SEATTLE--(BUSINESS WIRE)--Sept. 13, 2006--Targeted Genetics Corporation (Nasdaq:TGEN) today announced the issuance of a new patent that further strengthens the company's leadership in developing adeno-associated virus (AAV)-based therapies. U.S. Patent 7,105,345, titled "Adeno-Associated Virus Serotype 1 Nucleic Acid Sequences, Vectors And Host Cells Containing Same" covers compositions of AAV vectors that encode capsid proteins derived from AAV serotype 1 (AAV1) and host cells into which such vectors are introduced. The patent is a continuation of U.S. Patent #6,759,237 that provides additional protection around recombinant AAV vectors that Targeted Genetics is utilizing in several product development programs. The patent was issued to the University of Pennsylvania and is exclusively licensed to Targeted Genetics. The patent covers both AAV1 serotype and AAV1 pseudotyped vectors. Vectors of one serotype that are engineered to express capsid proteins of a different serotype are said to be "pseudotyped."
